Milei Threatens Falkland Oil Firms With Sanctions 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Xiaomi Shares Jump on Europe EV Expansion Plan 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
Dublin, Feb. 16, 2018 -- The "Biosimilar Insulin Market Access" report has been added to ResearchAndMarkets.com's offering.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.
Key Topics Covered:
EXECUTIVE SUMMARY
US
- Insights and strategic recommendations
- US payers are adopting a wait-and-see approach for biosimilar Basaglar
- Bibliography
FIVE MAJOR EU MARKETS
- Insights and strategic recommendations
- Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
- Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to
- reduce costs
- Payers use biosimilars to pressure originators on pricing
- Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
- Patient switching requires significant discounts of at least 30%
- Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
- Bibliography
METHODOLOGY
For more information about this report visit https://www.researchandmarkets.com/research/64x5p8/european_and_us?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Biosimilars and Biosuperiors
